We Work for Health of Massachusetts seeks to educate our elected leaders, the news media and the communities they serve about the important contributions these companies and their employees make to the health and economic security of individuals, local communities, and to the Commonwealth of Massachusetts.
The industry not only helps drive the Massachusetts economy, but also leads the world in life-saving research and supports a vibrant patient advocacy community. Biopharmaceutical research companies and their employees play a critical role in improving the health and well-being of Massachusetts’ patients by delivering life-saving, life-enhancing advancements in medicine. In addition to working to improve health and economic viability, many biopharmaceutical companies provide philanthropic outreach in local communities across Massachusetts through grants and programs supporting access to affordable health coverage and medicine, primary and secondary education, social services, arts, and other community needs.
The biopharmaceutical sector is the foundation of one of Massachusetts’ most dynamic innovation and business ecosystems. Not only does the industry invest heavily in the research and development of new treatments and cures, it also generates high quality jobs, powers economic output and exports for the U.S. economy and sustains a very large-scale supply chain.
Update
Learn more about We Work For Health in Massachusetts and how to get involved.
Supporting High Quality Jobs in Massachusetts
The innovative biopharmaceutical sector directly supported 72,147 jobs in Massachusetts in 2020. These jobs are often high-skill, high-wage professions.
The industry also supported another 216,443 jobs indirectly, for a total of about 288,590 jobs across the Massachusetts economy. These additional jobs are with vendors and suppliers such as construction companies and I.T. companies, and jobs generated by the sector’s employees such as day care centers and restaurants.
Massachusetts workers whose jobs were supported by the biopharmaceutical sector paid a total of $5.1 billion in personal taxes in 2020—$5.2 billion in federal taxes and $852 million in state taxes.
Massachusetts' Economic Impact
In 2020, the biopharmaceutical sector supported $81.1 billion in economic output for the state of Massachusetts—including $35.6 billion generated directly by the sector, and another $45.5 billion through its vendors and suppliers and through the economic activity of its workforce.
vendor relationships
vendor spending
$3,988,094,262
Partners
For more information on WWFH-MA, please contact us at info@weworkforhealth.org.
Join
Media
Going beyond his responsibilities as a researcher and leader, Miguel is extremely active in UCB's public affairs and PAC activities. He is a leader in local/state activities and engagements with the Massachusetts Life Sciences Association and is focused on expanding UCB's...
Going beyond his responsibilities as a researcher and leader, Miguel is extremely active in UCB's public affairs and PAC activities. He is a leader in local/state activities and engagements with the Massachusetts Life Sciences Association and is focused on expanding UCB's presence in the state. Furthermore, he has led a group of local, state and federal officials on a tour of UCB’s Bedford facilities to continue to build the company's narrative and reputation.
Phil is the Head of Chemistry and Pharmaceutical Sciences at Sunovion, but he also takes the time to participate in "State Researcher Fly-In Days." Before these events, he takes the time to research the legislators he will meet and then develops the key points for each...
Phil is the Head of Chemistry and Pharmaceutical Sciences at Sunovion, but he also takes the time to participate in "State Researcher Fly-In Days." Before these events, he takes the time to research the legislators he will meet and then develops the key points for each meeting. His research experience has impacted multiple meetings in key state capitals where the industry is working to ensure positive policy changes are implemented.
In addition to his role at Biogen, Chris and his team are an essential resource to the company's Public Policy and Government Affairs (PPGA) team. Chris and his team developed Biogen’s Pricing and Access Principles, which is a guiding post for Biogen with a focus on the value...
In addition to his role at Biogen, Chris and his team are an essential resource to the company's Public Policy and Government Affairs (PPGA) team. Chris and his team developed Biogen’s Pricing and Access Principles, which is a guiding post for Biogen with a focus on the value to patients, society, innovation, value, and affordability and sustainability. As the PPGA team advocates in D.C. and with state governments, Chris and his team are available to personalize the approach and perspective on complex biopharmaceutical issues.
